Multicenter retrospective analysis reveals effective CDK4/6i use in HR+/HER2− metastatic breast cancer patients, suggesting clinical factors aid treatment decisions.
CDK4/6i demonstrates favorable real-world efficacy in HR⁺/HER2⁻ MBC patients in central China, particularly in the first-line setting. Several clinical factors may aid in treatment selection and risk stratification.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: